MAPT and Alzheimer disease: Nonetheless, proteins in CSF that change at 8–10% per year are promising candidates that alone may be useful to track AD progression over time and may be complimentary with other AD disease progression markers such as volumetric imaging, contrast agents coupled with positron emission tomography (PET) imaging and the established biochemical markers such as Ab42, tau and p-tau.